Understanding Graft Versus Host Disease
An allogeneic stem cell or bone marrow transplant is a life-saving treatment typically used for blood cancers such as leukemia, lymphoma, and certain other blood disorders. During this procedure, the patient's diseased bone marrow is replaced with healthy stem cells from a donor. These donor cells rebuild the patient's immune system from the ground up. While this new immune system is essential for fighting the original cancer, it can also create a serious complication.
In graft versus host disease, the newly transplanted donor immune cells recognize the recipient's body as foreign. The donor's T-cells, a type of immune cell responsible for identifying threats, begin attacking the patient's own healthy tissues. GVHD can affect many parts of the body, including the skin, liver, lungs, digestive tract, and eyes. It can appear within weeks of the transplant (acute GVHD) or develop months to years later (chronic GVHD). Chronic GVHD is the form most commonly associated with severe eye involvement.
Ocular complications are remarkably common in patients with chronic GVHD. Research suggests that a significant percentage of patients who develop chronic GVHD will experience some form of eye involvement. The eyes are particularly vulnerable because the tear-producing glands, oil-producing glands, and the delicate surface tissues of the eye are all targets for the misdirected immune attack. For many transplant patients, eye symptoms become one of the most quality-of-life-affecting aspects of their GVHD.
The tissues that produce and maintain your tear film are exposed and accessible to circulating immune cells. The lacrimal glands (which produce the watery component of tears), the meibomian glands (which produce the protective oil layer), and the conjunctiva (the clear membrane lining the eyelids and covering the white of the eye) are all rich in the types of cells that donor T-cells tend to target. This makes the eye's entire tear production and maintenance system a prime site for immune-mediated damage.
How Ocular GVHD Damages the Eye
In ocular GVHD, aggressive donor T-cells heavily infiltrate the lacrimal glands. These are the glands located above and to the outer side of each eye that produce the watery layer of your tear film. As the immune cells attack and destroy the glandular tissue, the glands lose their ability to produce adequate tears. Over time, severe fibrotic scarring (the replacement of functional tissue with stiff scar tissue) can essentially shut down tear production. This leads to a profound level of dryness far beyond what is seen in typical dry eye disease.
The immune attack does not stop at the tear glands. The meibomian glands embedded in the eyelids are also infiltrated and damaged. These glands are responsible for producing the oil layer that prevents tears from evaporating too quickly. When the meibomian glands are destroyed by the inflammatory process, any tears that are still produced evaporate rapidly from the eye surface. This creates a dual problem: the eye makes far fewer tears, and the tears it does make disappear almost immediately.
The conjunctiva, the thin transparent tissue that lines the inside of the eyelids and covers the white part of the eye, is another target of the immune attack. The conjunctiva contains goblet cells that produce mucin, a slippery substance that helps tears spread evenly across the eye surface. When these goblet cells are destroyed, the remaining tears cannot adhere properly to the eye. The eye surface becomes dry, rough, and inflamed even in areas where some moisture remains.
As the immune attack continues, it triggers a cycle of chronic inflammation that leads to progressive fibrotic scarring throughout the eye's surface tissues. This scarring is not limited to the glands. It can affect the conjunctiva, the cornea (the clear front surface of the eye), and in severe cases, lead to symblepharon. Symblepharon is a condition where the inner surface of the eyelid scars directly to the surface of the eyeball, restricting eye movement and further damaging the cornea. This cycle of inflammation, tissue destruction, and scarring is what makes oGVHD so challenging to manage.
Without adequate tears and a healthy eye surface, the cornea becomes extremely vulnerable. Severe corneal dryness can lead to corneal epithelial breakdown (loss of the protective outer layer of cells), persistent corneal erosions (painful wounds that do not heal properly), corneal thinning, and in the most severe cases, corneal perforation (a hole forming in the cornea). These complications can lead to significant, potentially irreversible vision loss if not identified and treated promptly.
Recognizing the Symptoms of Ocular GVHD
Eye symptoms from GVHD can begin at any point after transplant, but they most commonly appear within the first one to two years. Early warning signs include a new sensation of dryness or grittiness in the eyes, increased sensitivity to light, a feeling of something foreign in the eye, and eyes that water excessively as a reflex response to the underlying dryness. Transplant patients who notice any of these symptoms should report them to both their transplant team and their eye care provider promptly.
As ocular GVHD progresses, the dryness becomes more severe and persistent. Patients often experience significant eye pain, burning that does not respond well to over-the-counter artificial tears, redness that persists throughout the day, and blurred vision that fluctuates with blinking. Reading, working on a computer, and being in air-conditioned or heated environments may become increasingly uncomfortable. Many patients describe a feeling that their eyes are 'running out of moisture' as the day goes on.
Severe ocular GVHD presents with profound, rapid-onset dryness, intense pain, and significant visual impairment. The clinical presentation often includes severe corneal staining (visible damage to the corneal surface detected during examination), thick mucous discharge, eyelids that stick together, and extreme light sensitivity. At this stage, the risk of serious corneal complications is high, and patients require urgent specialized care to prevent lasting damage.
While ocular GVHD shares many symptoms with common dry eye disease, there are important differences. The severity tends to be much greater, the onset can be rapid, and the response to standard artificial tears is typically poor. Patients with ordinary dry eye may find relief with regular use of eye drops and lifestyle adjustments. Patients with ocular GVHD often find that standard artificial tears are inadequate to manage their level of dryness. The TFOS DEWS III algorithm emphasizes that oGVHD requires treatments that go well beyond basic tear supplementation.
Treatment Approaches for Ocular GVHD
In typical mild to moderate dry eye, preservative-free artificial tears can provide meaningful relief by supplementing the tear film. In ocular GVHD, the destruction of the tear-producing glands, oil glands, and mucin-producing cells is so extensive that simply adding moisture to the eye surface cannot compensate for the losses. The TFOS DEWS III treatment algorithm states that oGVHD requires immediate escalation to advanced therapies rather than relying on basic lubricants alone. While artificial tears may still be used as a supportive measure, they are only a small part of a much larger treatment plan.
Controlling the inflammatory process is central to managing ocular GVHD. Topical corticosteroid eye drops can help reduce the active inflammation that drives tissue destruction. These are potent medications that require careful monitoring by an eye care provider because long-term use carries risks including increased eye pressure and cataract formation. Topical immunomodulators, which are medications that calm the immune response without the risks of steroids, are often used alongside or as alternatives to corticosteroids for longer-term inflammation control.
Autologous serum eye drops are a specialized treatment made from the patient's own blood. A sample of the patient's blood is drawn, processed to separate the serum (the clear liquid portion), and then diluted to create custom eye drops. These drops contain natural growth factors, vitamins, and anti-inflammatory compounds that closely mimic the composition of natural tears. For patients with oGVHD whose tear glands can no longer produce adequate natural tears, autologous serum drops can provide nourishment and healing support that conventional artificial tears cannot.
For patients with severe ocular GVHD, rigid scleral contact lenses are often a critical component of treatment. These are large-diameter lenses that vault over the entire cornea without touching it. The space between the lens and the cornea is filled with saline solution, creating a continuous liquid reservoir that bathes the damaged corneal surface throughout the day. This reservoir protects the cornea from exposure, reduces pain, improves vision, and creates an environment that supports healing. The TFOS DEWS III guidelines recognize scleral lenses as an important therapeutic tool for severe dry eye conditions.
Because ocular GVHD is part of a systemic disease, its management must be coordinated with the overall GVHD treatment plan. Systemic immunosuppressive medications prescribed by the transplant team to control GVHD throughout the body may also help reduce the immune attack on the eyes. Your eye care provider and your transplant specialist need to communicate regularly to ensure that your eye treatments are compatible with your systemic therapies and that changes in one area of treatment do not negatively affect another.
Living with Ocular GVHD
Early detection and treatment of ocular GVHD can slow or limit the damage to the tear-producing system. All patients who undergo allogeneic stem cell or bone marrow transplants should have a baseline comprehensive eye examination before or shortly after the procedure. Regular follow-up eye exams should continue for years after transplant, even if no eye symptoms are present initially. At Washington Eye Institute, our multidisciplinary ophthalmology and optometry team works with transplant patients to monitor eye health over time and intervene early when changes are detected.
Patients with ocular GVHD can take steps to reduce the burden on their compromised tear system. Using a humidifier at home and at work helps maintain moisture in the air. Wearing wraparound glasses or moisture chamber glasses outdoors reduces tear evaporation caused by wind. Avoiding direct airflow from fans, heaters, and air conditioning vents protects the eyes from drying. Taking frequent breaks during reading or screen work allows the tear film to recover. These measures do not replace medical treatment, but they can meaningfully improve daily comfort.
Living with ocular GVHD after surviving a serious blood cancer can be emotionally challenging. Patients who have endured the rigors of transplant often expect to feel better once the cancer is treated, only to find that chronic eye pain, vision problems, and ongoing medical appointments create a new source of daily struggle. It is important to acknowledge these feelings and seek support. Many transplant centers offer support groups and counseling services. Your eye care team can also help by setting realistic expectations, celebrating improvements, and adjusting treatment plans to minimize the impact on your daily life.
Managing ocular GVHD effectively requires a team approach. Your transplant specialist manages the systemic aspects of GVHD. Your eye care provider manages the ocular components. Ideally, these providers communicate with each other about your treatment plan. As a patient, you play an important role by reporting new or worsening eye symptoms promptly, attending scheduled eye examinations, using your prescribed treatments consistently, and asking questions when something is unclear. Keeping a brief daily log of your eye symptoms can help your care team identify trends and adjust your treatment.
The course of ocular GVHD varies from person to person. Some patients experience a period of active disease that eventually stabilizes with appropriate treatment. Others may have a more chronic course that requires ongoing management. While the damage to the tear-producing glands may not be fully reversible, many of the treatments available today can significantly reduce symptoms, protect the cornea, and preserve functional vision. Advances in understanding the immune mechanisms behind GVHD continue to lead to new treatment approaches. Staying engaged with your care team and following your treatment plan gives you the best chance of maintaining comfort and vision over the long term.
Frequently Asked Questions
Ocular GVHD can develop at any time after an allogeneic stem cell or bone marrow transplant. Acute GVHD may appear within the first few months, while chronic GVHD, which is more commonly associated with severe eye involvement, typically develops three months to two years after transplant. However, some patients develop eye symptoms even later. This is why ongoing eye monitoring is recommended for all transplant recipients, even years after the procedure.
No. While ocular GVHD causes severe dry eye symptoms, it is fundamentally different from common dry eye disease. In typical dry eye, the tear system may be underperforming but is usually still partially functional. In ocular GVHD, the donor immune cells actively attack and destroy the glands that produce tears, oil, and mucin. The severity is typically much greater, the risk of serious complications is higher, and the treatments required are more advanced. Ocular GVHD is classified as one of the most severe forms of inflammatory dry eye.
If left untreated or inadequately managed, severe ocular GVHD can lead to serious corneal damage, including corneal perforation, which may result in significant and potentially lasting vision loss. However, with early detection, aggressive treatment, and ongoing monitoring, many patients can preserve functional vision. The goal of treatment is to control inflammation, protect the corneal surface, and maintain as much comfort and visual function as possible.
At Washington Eye Institute, our multidisciplinary ophthalmology and optometry team provides comprehensive eye exams to evaluate and monitor the health of the tear film, cornea, and eye surface in transplant patients. Our team can identify early signs of ocular GVHD, coordinate with your transplant specialists, and develop a personalized management plan. We offer treatments including IPL therapy and punctal plugs as part of a broader dry eye management approach, and we can help guide you to additional specialized care as needed.
Patients with ocular GVHD should avoid environmental factors that worsen dryness. This includes direct exposure to wind, air conditioning or heating vents blowing toward the face, smoky or dusty environments, and prolonged screen use without breaks. It is also important to avoid rubbing your eyes, as the compromised corneal surface is more vulnerable to injury. Follow your eye care provider's guidance on which products are safe to use around your eyes, and use only the eye drops and medications your provider has recommended.
In some cases, improvement in systemic GVHD is accompanied by improvement in the eye symptoms, particularly if the immune attack on the ocular tissues slows down. However, the damage to the tear glands and meibomian glands may be partially or fully irreversible due to fibrotic scarring that occurred during the active disease phase. This means that even when systemic GVHD improves, many patients continue to need ongoing eye treatments to manage residual dryness and protect the corneal surface. Your eye care provider can help adjust your treatment plan as your overall condition evolves.